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Interaction of fluoroquinolone antibiotic drugs, viz., ciprofloxacin hydrochloride, levofloxacin hemihydrate and 
lomefloxacin hydrochloride, with the cationic surfactant cetyldimethylethylammonium bromide (CDMEAB) has been 
studied by conductance measurements in water and in the presence of salts such as NaCl, Na2SO4 and Na3PO4·12H2O over 
the temperature range of 298.15–318.15 K. Two critical micelle concentrations (c*) are obtained for drug-CDMEAB 
systems in all the cases. The change of c* values of CDMEAB due to the addition of the drugs is indicative of the 
interaction between drugs and CDMEAB. Favourable micellization of drug-CDMEAB systems is observed in the presence 




m reveal that the binding interactions 
between drug and CDMEAB in water are both electrostatic and hydrophobic in nature. The existence of linear correlation 
between ∆H0m and ∆S
0
m values is observed in all cases. 
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Fluoroquinolones
Surfactants have been widely used in numerous  
fields such as foodstuffs, cleaning products, paints, 
cosmetics, oil recovery, waste water treatment, 
various separation process and pharmaceutical 
industry
1-4
. The affinity to aggregate in solutions to 
form micelles above a critical concentration,  
known as critical micelle concentration, is one of the 
characteristic properties of surfactants. Different 
physico-chemical phenomena such as micellar 
solubilization, micellar catalysis, reduction of surface 
tension, tertiary oil recovery, solute-sovent and 
solute-solute interactions are dependent on the critical 
micelle concentration
3,5
. Drug-membrane interactions 
are believed to be analogous to the interactions 
between drugs and surfactants. Surfactant micelles 
have thus been accepted as simplified model of 
biomembranes. In addition, surfactants are used to 
enhance the water solubility of many pharmaceutical 
components which is a difficult problem in 
formulation of an acceptable dosage form
6-8
. The 
interpretation of the interaction of drugs with 
surfactant micelles can be visualized as estimation for 
their interactions with biological surfaces. Also, 
characterization of drug-surfactant interactions is 
important in pharmacology and for developing better 
pharmaceutical formulations. The changes in 
surfactant structure and nature of the counter ions, 
added electrolytes, temperature, etc., can modify 
significantly the size, flexibility and type of 
interactions of surfactant micelles. Hence, interaction 
of drugs with surfactants has been studied by chemists 
and biochemists with increasingly growing research 
interest. Ismail et al.
9
 investigated the interaction 
between tetracaine hydrochloride (THC) with sodium 
deoxycholate (SDC). They determined the critical 
micelle concentrations and observed synergistic 
behavior. They also observed that the mixed micelles 
appear to have spherical and prolate ellipsoidal shapes. 
In our early papers, we reported the interaction  
of cephalosporin drugs with ionic surfactants
10-14
. 
Literature survey reveals that a detail study regarding 
drug-surfactant interactions is still necessary.  
Fluoroquinolones are broad spectrum synthetic 
antibiotics, which are advised as oral drugs to treat 
bacterial infections such as bronchitis, complicated 
urinary tract infections, respiratory tract infections 
bone and joint infections, intra-abdominal infections 
and to prevent urinary tract infections prior to  
surgery. In the present study, the interactions of 
fluoroquinolones drugs, namely, ciprofloxacin 




hydrochloride (CPFH), levofloxacin hydrochloride 
(LVFH) and lomefloxacin hydrochloride (LMFH) 
with the cationic surfactant cetyldimethylethylammonium 
bromide (CDMEAB) have been undertaken using 
conductometric technique. To study the drug-
CDMEAB interactions, values of critical micelle 
concentration (c*), fraction of counter ion binding (β) 









p,m associated with the drug mediated 
CDMEAB micellization in pure water as well as in 
different salt solutions like NaCl, Na2SO4 and 
Na3PO4.12H2O have been determined.  
 
Materials and Method 
CDMEAB (Acros Organics, USA, 99%), USP 
standard sample of drugs such as CFH, LFH and 
LMFH (provided by General Pharmaceuticals Ltd., 
Bangladesh; 98%), NaCl (BDH, England, 99.5%), 
Na2SO4 (Merck, Mumbai, 99%) and Na3PO4.12H2O 
(Merck, Mumbai, 99%) were used as received  
 All solutions were prepared by using distilled, 




The specific conductances of the drug-CDMEAB 
systems, both in water/water-salts mixed media,  
were measured using a 4510 conductivity meter 
(Jenway, UK) with a temperature-compensated cell 
(cell constant: 0.97 cm
-1
) following the procedure 
reported in the literature
10-13,14,15
. Water/drug solution 
(20 mL) of a particular concentration was taken in  
a test tube immersed in a thermostatic water bath  
and then known volume of concentrated CDMEAB 
solution in water/ drug solution of same concentration 
was gradually added to the water/ drug solution with  
a pipette. After thoroughly mixing and allowing  
time for temperature equilibration, the conductance  
of the mixed system was recorded in each case. The 
temperature of the drug-CDMEAB systems was 
maintained with the help of Lauda water thermostated 
bath with precision of ±0.1 K. To study the effect of 
salts such as NaCl, Na2SO4, and Na3PO4.12H2O on 
interaction of the drugs with CDMEAB, the solutions 
of drug and CDMEAB were prepared in (water+salt) 
and in (water+drug+salt) media respectively in such  
a way that both solutions contained the same 
concentration of drug and salt. The critical micelle 
concentration (c*) of drug-surfactant system was 
determined from the break point observed in the 
specific conductance (κ) versus concentration of 
surfactant (cCDMEAB) plot. 
Results and Discussion 
 
Micellar parameters of drug-CDMEAB systems 
The specific conductance (κ) value of CDMEAB 
solutions is found to change with the addition of drugs 
in water as well as in presence of salts as shown by a 
typical plot of κ versus concentration of CDMEAB 
(cCDMEAB) for CFH–CDMEAB system in water at 
303.15 K (Fig. 1). In this plot, two breakpoints  
are observed in both pure water and in aqueous 
solutions of salts. The cCDMEAB corresponding to the 
breakpoints, i. e., critical micelle concentration, are 
labeled as c*1 and c*2 (refs 10-18). The c*1 reveals the 
concentration of surfactant at which association 
between drug and surfactant starts, while c*2 indicates 
CDMEAB micelle formation in presence of drug
11
. 
For different systems, more than one c*
 
value is also 
reported in the literature by others and us
11-15,17,18
.  
In our previous study, we reported the values of c*1 
and c*2 of CDMEAB in water at 303.15 K to be 0.90 
and 3.70 mM respectively
11
. The degree of ionization 
of micelles (α) was determined from the slopes of  
the straight lines above and below c* (refs 10-18). 
The fraction of counter ion binding, β at c* was 
determined by deducting the value of α from unity, 
i.e., β = 1–α.  
The values of c* and β for the drug-CDMEAB 
system in water containing different concentrations  
of drugs at 303.15 K are shown in Fig. 2 (see also 
Supplementary Data, Table S1). The c* values for 
CFH-CDMEAB are higher and lower than the pure 
CDMEAB systems in water at lower and higher  
CFH concentrations respectively at 303.15 K. In  
the case of LFH-CDMEAB and LMFH-CDMEAB 
 
 
Fig. 1 – Specific conductivity (κ) versus concentration of 
CDMEAB for CFH-CDMEAB system in water at 303.15 K. 






 values are higher in magnitude than 
that of pure CDMEAB in water at 303.15 K, except 
the c*1 value for LMFH-CDMEAB system containing 
0.5 mM drug. For CFH-CDMEAB system in water, 
the c* values first increase with CFH concentration, 
attain a maximum and then the values tend to 
decrease with further increase in CFH concentration. 
For LFH-CDMEAB and LMFH-CDMEAB  
systems, the c* values initially decrease with drug 
concentration, attain a minimum and then the values 
tend to increase with further increase in CFH 
concentration. The change of c* values of CDMEAB 
with the addition of drugs show the interaction 
between drug and CDMEAB. At 303.15 K, the c*1 
values of drug-CDMEAB systems containing  
0.50 mM drug are found to follow the order:  
c*LFH-CDMEAB ˃ c*CFH-CDMEAB ˃ c*LMFH-CDMEAB, whereas 
c*2 values are found to follow the order: c* CFH-CDMEAB ˃ 
c* LFH-CDMEAB ˃ c*LMFH-CDMEAB. The differences of c*
 
values for drug-CDMEAB systems are due to the 
structural variation of the drugs used.  
The c* and β values for drug-CDMEAB systems at 
303.15 K in aqueous solution of salts such as NaCl, 
Na2SO4 and Na3PO4 are shown in Figs 3-5 (see also 
Supplementary Data, Table S2). The c
*
1 values of 
drug-CDMEAB systems at 303.15 K in salts solution 
are found to decrease with increase of ionic strength 
(I) of salts except the c*1 value for LFH-CDMEAB 
system in aqueous solution of Na2SO4 having ionic 
strength of 0.50 mM. The c*2 values of drug-
CDMEAB systems at 303.15 K in salts solution 
decrease up to a certain ionic strength of salts, attain 
minimum and then increase with increase of the ionic 
strength of salts. The c*1 values of CFH-CDMEAB 
system at 303.15 K at I = 0.50 mM of drug followed 
the order: cNaCl ˃ cNa2SO4 ˃cNa3PO4, whereas c*2 values 
follow the order: cNaCl ˃ cNa3PO4 ˃ cNa2SO4 under the 
same experimental condition. This change of c* 
 
 
Fig. 2 – Values of (a) c*1 versus concentration of drug (cdrug ) and (b) c*2 versus concentration of drug (cdrug ) for LFH-CDMEAB (1, ♦), 




Fig. 3 – Values of (a) c*1 versus concentration of salt (cNaCl) and (b) c*2 versus concentration of salt (csalt) for LFH-CDMEAB (1, ♦), 
LMH-CDMEAB (2, ▲), and, CFH-CDMEAB (3, ■) systems in aqueous solution of NaCl. 
 




values may be due to the presence of ions of different 
nature. Chloride (Cl
-
) ion is a moderate chaotrope, 
having a large singly charged ion with low charge 
density, ruptures water structures and weakens the 
stability of hydrophobic aggregates of surfactant 
molecules. Both sulfate and phosphate are strong 
kosmotropes, having small multi-charged ion with 
high charge density. They interact with water strongly 
as water structure makers and stabilize the 
hydrophobic aggregates of CDMEAB molecules. 
Thus, Na2SO4 and Na3PO4 salt out the hydrophobic 
chains of surfactants from aqueous medium and lower 
the c* values of surfactant system significantly as 
compared to that of NaCl. The kosmotropic effect of 
the anions of sodium salts having ionic strength of  





. This is in good agreement 
with the observed results of the effect of salts on the 
critical micelle concentration of cetylpyridinium 
chloride
19
. With addition of salt, a decrease of c* 
values was observed for the micellization of 
surfactants in the presence of drug
10-12, 20- 22
. The total 
effect of an electrolyte is the sum of its effects on the 
drug and surfactant molecule in association with the 
aqueous phase. Hydrophilic groups of the surfactant 
molecules are directed towards the aqueous phase 
both in the monomeric and micellar forms of the 
surfactant, while the hydrophobic groups are 
surrounded by water only in the monomeric form of 
surfactant molecules. Thus, the consequence of the 
electrolyte on the hydrophilic groups in the 
monomeric and micellar forms may eliminate each 
other and hence the effects of electrolyte on the 
hydrophobic groups of surfactant monomers play  
the dominating role. 
The values of c* and β at different temperatures  
for drug-CDMEAB systems in pure water and in the 
presence of salts such as NaCl, Na2SO4 and Na3PO4 
 
 








) for LFH-CDMEAB (1, ♦), 












) for LFH-CDMEAB (1, ♦), 
LMH-CDMEAB (2, ▲), and, CFH-CDMEAB (3, ■) systems in aqueous solution of Na3PO4. 
 




are summarized in Fig. 6 (see also Supplementary 
Data, Tables S3 & S4 and Figs S1–S6). The c*1 
values at different temperatures in pure water for 
CFH-CDMEAB and LFH-CDMEAB systems are 
found to increase gradually with increasing 
temperatures up to a certain temperature, attain a 
maximum value and then decrease with further 
increasing temperature. For LMFH-CDMEAB 
system, the c*1 values at different temperatures 
decrease gradually up to a maximum and thereafter 
the values gradually increase with further increasing 
temperature. The c*2 values for all the drug-
CDMEAB systems initially decrease, pass a minimum 
value and then tend to increase with further increase 
of temperature. In the presence of NaCl, Na2SO4 and 
Na3PO4 salts, the c* values for all the drug-CDMEAB 
systems are initially found to decrease, pass through a 
minimum and then tend to increase with further 
increase of temperature. Such a type of variation of 
the c
*
 values for different systems containing ionic 
surfactants and more often containing non-ionic 
surfactant are also reported in the literature
10-12,23
.  
In some cases the trend of gradual increase of c* 
values with increasing temperature is also reported
16,24
. 
The change of c* values with temperature can be 
explained with the change of the mode of hydration 
surrounding the surfactant monomers as well as the 
drug mediated CDMEAB micelles. In monomeric 
form of surfactant, both hydrophobic and hydrophilic 
hydrations are possible, whereas only hydrophilic 
hydration is possible for micellized CDMEAB. Both 
types of hydrations are expected to decrease with 
increase of temperature. A decrease in hydrophilic 
hydration favours the micelle formation, while a 
decrease of hydrophobic dehydration with the increase 
of temperature oppose the micelle formation
12,13,16,23,25
. 
Thus, the magnitude of these two factors determine 
whether the c* values increase or decrease over a 
particular temperature range. The minimum in c* 
versus temperature plots has been explained earlier 
considering the change in various factors like 
surfactant solubility, desolvation, change in solvent 
structure, etc., with temperature which may play an 




Thermodynamic parameters of drug-CDMEAB systems 
Thermodynamic parameters are an effective tool  
to study the mode of interaction at the molecular 
level. The thermodynamic parameters of studied  
drug-CDMEAB systems containing 1:1 electrolyte 










m = - (1+β) RT
2








m)/ T …(3) 
 
where values of c* are in mole fraction unit. Plot 
ln(c*2) versus T was nonlinear (Fig. 7) and the slope 
of the tangent drawn at each temperature of ln(c*2) 






The values of thermodynamic parameters for  
drug-CDMEAB systems in pure water and in the 
presence of NaCl, Na2SO4 and Na3PO4 salts are 
presented in Tables 1 and 2. The ∆G
0
1, m and ∆G
0
2, m 
values for all the systems are found to be negative, 
which indicates that the micellization process is 
thermodynamically spontaneous.  
For CFH-CDMEAB in water, the ∆H
0
1,m values are 
found to be positive and the values decrease with 
temperature and the sign of ∆H
0
1,m value changes 
from positive to negative at the elevated temperature. 
 
 
Fig. 6 – Plot of (a) c*1 vs. T and (b) c*2 vs. T for LFH-CDMEAB (1, ♦), LMH-CDMEAB (2, ▲), and, CFH-CDMEAB (3, ■) systems in 
water containing 0.50 mM drugs at different temperatures. 




The  values  of  ∆S
0
1,m  are  found  to  be  positive  and  
the values decrease gradually with increasing 
temperature. Thus, the first aggregation process was 
found to be entropy controlled at lower temperature 
and becomes both enthalpy and entropy controlled at 
higher temperature. For CFH-CDMEAB system in 
water, the ∆H
0
2,m values are negative and the values 
decrease with increasing temperature. The values of 
∆S
0
2,m are negative at lower temperatures, and the sign 
changes from negative to positive with the positive 
values increasing with increase of temperature. Thus 
the CFH mediated CDMEAB micellization process  
is enthalpy controlled at lower temperatures and 
becomes both enthalpy and entropy controlled at 
higher temperatures. The results reveal that the 
binding interactions between CFH and CDMEAB are 
both electrostatic and hydrophobic in nature, although 
hydrophobic contribution plays the major role. In 
aqueous solution of NaCl salt, the ∆H
0
1,m values are 
found to be negative at lower temperatures and 
positive at higher temperatures. The ∆H
0
2,m values are 
found to be positive at lower temperatures and 





2,m are positive, and the values increase 
gradually with increase of temperature. Thus, the first 
micellization at lower temperatures is both enthalpy 
and entropy controlled while at higher temperatures in 
presence of NaCl, it becomes entropy controlled. The 
second micellization process was entropy controlled 
at lower temperatures and becomes both entropy  
and enthalpy controlled at higher temperatures.  
The change of thermodynamic parameters in aqueous  
 
Table 1 – Thermodynamic parametersa for the micellization of the drug-CDMEAB systems containing 0.50 mM drug in water  
at different temperatures 













 (K) (kJ mol-1) (kJ mol-1) (kJ mol-1) (kJ mol-1) (J mol-1 K-1) (J mol-1 K-1) (kJ mol-1 K-1) (kJ mol-1 K-1) 
CDMEAB 298.15 -46.60 -41.85 -61.38 -41.21 -49.57 2.18   
 303.15 -49.68 -43.59 -32.99 -23.02 55.03 67.87   
 308.15 -51.02 -44.76 -1.04 -2.01 162.2 138.7 6.51 4.23 
 313.15 -51.00 -45.26 32.84 19.90 267.7 208.1   
 318.15 -51.23 -45.39 68.42 43.17 376.1 278.3   
CFH-CDMEAB 298.15 -50.34 -41.52 29.86 -8.24 268.9 -122.3   
 303.15 -50.59 -42.87 22.66 -7.23 241.6 -13.53   
 308.15 -50.95 -44.21 15.03 -5.4 214.1 98.73 -1.58 6.88 
 313.15 -50.93 -44.92 6.84 -3.07 184.5 213.9   
 318.15 -52.09 -44.61 -1.68 0.69 158.4 327.2   
LFH-CDMEAB 298.15 -46.76 -41.61 67.99 -23.81 384.9 59.69   
 303.15 -47.31 -42.64 44.04 -19.53 301.3 76.25   
 308.15 -45.84 -42.97 17.79 -14.67 206.5 91.83 -5.37 0.98 
 313.15 -47.91 -45.02 -9.62 -9.48 122.3 113.4   
 318.15 -49.59 -45.59 -39.34 -4.36 32.23 129.5   
LMFH-CDMEAB 298.15 -46.60 -41.85 -61.38 -41.21 -49.57 2.18   
 303.15 -49.68 -43.59 -32.99 -23.02 55.03 67.87   
 308.15 -51.02 -44.76 -1.04 -2.01 162.2 138.7 6.51 4.23 
 313.15 -51.00 -45.26 32.84 19.90 267.7 208.1   
 318.15 -51.23 -45.39 68.42 43.17 376.1 278.4   






m values are: ±0.04–0.2 kJ mol
-1; ±0.03 kJ mol-1; ±0.04–0.2 J mol-1 K-1
and 0.02–0.1 kJ mol-1 K-1 respectively. 
 
 
Fig. 7 – ln(c*1) versus T for CFH-CDMEAB system in water. 






Table 2 – Thermodynamic parametersa for the micellization of the drug-CDMEAB systems in 0.50 mM aqueous salt solutions  
at different temperatures 















 (K) (kJ mol-1) (kJ mol-1) (kJ mol-1) (kJ mol-1) (J mol-1 K-1) (J mol-1 K-1) (kJ mol-1 K-1) (kJ mol-1 K-1) 
H2O-NaCl 
CFH–CDMEAB 298.15 -49.49 -41.86 -45.89 17.05 12.06 47.84   
 303.15 -51.9 -42.95 -19.22 3.76 107.79 90.72   
 308.15 -51.79 -44.15 9.3 -2.64 198.24 135.98 5.85 2.73 
 313.15 -51.57 -44.73 39.61 -14.4 291.17 181.42   
 318.15 -51.86 -44.65 71.04 -28.26 386.3 225   
LFH–CDMEAB 298.15 -48.40 -41.47 -24.35 -44.06 80.67 -8.67   
 303.15 -49.79 -43.15 -8.55 -23.43 136.02 65.05   
 308.15 -49.55 -44.27 8.41 -1.18 188.08 139.83 3.50 4.65 
 313.15 -50.34 -44.21 26.52 23.96 245.43 217.69   
 318.15 -50.99 -44.87 45.58 48.47 303.54 293.38   
LMFH–CDMEAB 298.15 -49.72 -41.95 -27.64 -26.84 74.06 50.68   
 303.15 -50.82 -43.01 -15.83 -14.61 115.44 93.69   
 308.15 -52.40 -44.24 -3.01 -0.99 160.29 140.34 2.62 2.76 
 313.15 -52.48 -44.25 10.45 13.19 200.96 183.44   
 318.15 -52.44 -44.69 24.84 28.25 242.90 229.27   
H2O-Na2SO4 
CFH–CDMEAB 298.15 -49.19 -42.73 -50.51 12.31 -4.45 218.25   
 303.15 -50.79 -43.10 -30.12 5.77 68.17 176.01   
 308.15 -51.74 -43.77 -8.09 1.4 141.65 132.4 4.52 -2.72 
 313.15 -52.23 -44.75 15.43 -2.53 216.09 88.47   
 318.15 -51.97 -45.74 39.68 -8.48 288.06 43.44   
LFH–CDMEAB 298.15 -49.09 -43.36 -0.16 11.65 164.10 184.53   
 303.15 -49.66 -43.88 16.75 9.73 219.07 176.85   
 308.15 -49.76 -44.55 34.87 7.70 274.63 169.56 3.67 -0.43 
 313.15 -49.87 -45.31 54.83 5.38 334.32 161.86   
 318.15 -48.32 -45.29 72.45 3.05 379.62 151.92   
LMFH–CDMEAB 298.15 -50.28 -42.21 -73.71 -40.31 -78.57 6.37   
 303.15 -53.14 -43.43 -21.14 -22.65 105.56 68.56   
 308.15 -51.12 -43.93 35.18 -2.41 280.07 134.72 11.12 3.98 
 313.15 -51.28 -44.70 94.68 18.17 466.11 200.75   
 318.15 -46.56 -42.74 146.31 38.68 606.24 255.91   
H2O-Na3PO4 
CFH–CDMEAB 298.15 -52.46 -43.30 47.59 -5.94 335.57 305.25   
 303.15 -52.25 -43.18 40.75 -5.64 306.78 213.92   
 308.15 -50.84 -43.65 33.53 -7.82 273.82 123.55 -1.44 -5.62 
 313.15 -51.31 -44.27 26.44 -6.73 248.29 30.97   
 318.15 -51.02 -45.64 18.81 -5.52 219.48 -60.12   
LFH–CDMEAB 298.15 -48.48 -44.27 22.90 59.41 239.39 347.75   
 303.15 -49.79 -44.84 25.92 47.35 249.75 304.12   
 308.15 -49.74 -44.39 28.62 33.92 254.29 254.13 0.52 -2.80 
 313.15 -50.08 -44.63 31.72 18.52 261.23 201.66   
 318.15 -48.01 -44.37 33.08 3.80 254.86 151.41   
LMFH–CDMEAB 298.15 -50.07 -42.51 -104.23 -23.69 -181.65 63.14   
 303.15 -51.13 -43.62 -58.11 -25.36 -23.00 60.22   
 308.15 -52.59 -44.77 -9.41 -26.94 140.12 57.85 9.92 -0.33 
 313.15 -51.87 -45.78 40.30 -28.66 294.31 54.66   
 318.15 -51.83 -46.77 94.51 -30.32 459.99 51.69   






m values are: ±0.05–0.2 kJ mol
-1; ±0.05–0.2 kJ mol-1; ±0.05–0.3 J mol-1 K-1
and 0.02–0.1 kJ mol-1 K-1 respectively. 
bDrug = 0.50 mM.  




solution of Na2SO4 is found to be almost similar to 
that in NaCl. However, the exothermic contribution 
on first aggregation process and the hydrophobic 
contribution on second micellization process are 
dominant at lower temperatures in the case of Na2SO4 
as compared to that of NaCl. In presence of Na3PO4, 
the first micellization process is entirely entropy 
controlled, whereas the second micellization process 
is both entropy and enthalpy controlled within the 





2,m with temperature (T) for the micellization of 
CFH-CDMEAB system in water and in aqueous 
solution of salts is shown in Figs S7 and S8 
(Supplementary Data). 
For LFH–CDMEAB system in water, the ∆H
0
1,m 
values are positive at lower temperatures. The values 
decrease with temperature, the sign changes from 
positive to negative and the negative values tend to 
increase gradually with increase of temperature. The 
and ∆H
0
2,m values are negative and the negative 
values are found to decrease gradually with increase 
of temperatures. The ∆S
0
m values over the range of 







values are found to decrease and increase 
respectively with increase of temperature. Thus, the 
micellization process is only entropy controlled at the 
lower temperatures while at higher temperatures there 
is also enthalpic contribution in addition to entropy 
effect. These results reveal that the binding 
interactions between LFH and CDMEAB are both 
electrostatic and hydrophobic in nature, while 
hydrophobic contribution plays the major role in the 





m values reveal that the micellization 
processes are almost entropy controlled though there 
is some enthalpy effect at the lower temperatures in 
aqueous NaCl solution.  





2,m values are negative at lower temperatures, 
the sign changes from negative to positive and the 
positive values tend to increase gradually with 
increase of temperature. The value of ∆S
0
1,m at  





2,m values are found positive with the values 
increasing gradually with increase of temperature. 
Thus, the micellization processes are both entropy  
and enthalpy controlled at lower temperatures, and 
become only entropy controlled at the elevated 
temperatures. The results reveal that the binding 
interactions between LMFH and CDMEAB are  
both electrostatic and hydrophobic in nature, while 
hydrophobic contribution plays the major role.  





m values follows almost the same trend as that in 





m reveal the enhanced binding interactions 




m is expected to be the sum of the 
change in enthalpies arising from hydrophobic 
interactions, electrostatic interactions and hydration 
of polar head groups. A negative ∆H
0
m may occur 
when second and third effects become dominant 
while the positive ∆H
0
m may arise when the first 
effect is stronger. The negative values of ∆H
0
m 
signify the importance of London-dispersion 
interactions as an attractive force of micellization 
between drug-surfactant systems
33
, whereas the 
positive ∆H
0
m values indicate the breaking of 
structured water around the hydrophobic parts of the 
molecules
34
. The positive values of ∆S
0
m for drug 
mediated surfactant micellization can be explained 
considering two factors. These are: (i) transfer of 
hydrophobic chains from hydrated form in aqueous 
medium to the nonpolar interior of the micelle 
destroying iceberg structures, and, (ii) increase of 
rotational degree of freedom of hydrophobic chains 
in the micelle interior as compared to the aqueous 
environment
35,36
. The negative values of ∆S
0
m may 
occur when the formation of iceberg structure 
surrounding the drug and CDMEAB is dominant 
over the above two effects.  
The enthalpy change with temperature, i.e., the 
molar heat capacity changes (∆mC
0
p) for micelle 
formation, is an important sign of protein structural 
changes in response to different ligands which is 













The enthalpy change with temperature, i.e. the 
molar heat capacity, varies linearly with temperature 
for all the drug-CDMEAB systems in pure  
water as well as in the aqueous solution of salts.  
The values ∆mC
0
p of the drug-CDMEAB systems 
were found to be positive in some cases and  
negative for others. The change in heat capacity 
associated with drug-CDMEAB binding is believed 
to be associated with motion restriction and is 
proportional to the change in the surface area 




accessible to the solvent
38
. However, the small ∆mC
0
p 
and the positive binding entropy indicate minor 
structural rearrangement of CDMEAB micelle 
during binding with LMFH, whereas in the case of 
aggregation the effect was significant at lower 
temperatures.  
A linear relationship between ∆H
0
m and  
∆S
0
m, i.e., enthalpy-entropy compensation, with R
2  
in the range of 0.993-0.999 was observed in all cases 













where the slope, Tc the compensation temperature, 
describes the solvation part of the micellization 
process and is the basis of comparison for  
different examples of compensation behavior and  
the intercept ∆H
0,
*m, is the intrinsic enthalpy gain. 
The intercept ∆H
0
*m characterizes the solute-solute 
interaction and is an index of the efficacy of the 
hydrophobic chain to participate in the micelle 
growth. The values of ∆H
0
m and Tc for both systems  
in pure water and in the presence of salts are  
shown in Table 3. The Tc values for drug-CDMEAB 
systems are slightly higher in the presence of salts 
than in pure water. The Tc value in the range of  
275-581 K has been used as an indicator for the 





*m values indicates that the micellization 
of CDMEAB was facilitated even at ∆S
0
m = 0. An 
increase in the negative ∆H
0,
*m values indicates the 
stability of the formation of the micelles.  
Conclusions 
Interaction of three fluoroquinolone drugs with  
the cationic surfactant, CDMEAB, was studied  
by conductance measurements in water and in the 
presence of salts. The addition of drugs altered  
the micellization behaviour of CDMEAB. In addition, 
the effect of temperatures and presence of salts is  
also observed significantly. The thermodynamic 
parameters reveal that drug-CDMEAB interactions 
are mainly hydrophobic and electrostatic in nature. 
 
Supplementary Data 
Supplementary Data associated with this article, 
Figs S1-S8 and Tables S1-S4 are available in the 
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